Evidence map›Paper›PMID 33869071›Full record

ArticleFrontiers in oncology2021

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection.

Jiashuo Chao, Qi Zhu, Desheng Chen, Xiao An, Aiqun Liu, Fei Zhou, Lin Yuan, Zhaowen Wang, Hongcheng Sun

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jiashuo ChaoDepartment of General Surgery, Shanghai Organ Transplantation Medical Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Qi ZhuDepartment of General Surgery, Shanghai Organ Transplantation Medical Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Desheng ChenDepartment of General Surgery, Shanghai Organ Transplantation Medical Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Xiao AnDepartment of Neoplasms and Interventional Radiology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Aiqun LiuDepartment of Radiology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Fei ZhouDepartment of Oncology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Lin YuanDepartment of Pathology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhaowen WangDepartment of General Surgery, Shanghai Organ Transplantation Medical Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Hongcheng SunDepartment of General Surgery, Shanghai Organ Transplantation Medical Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Shanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTransarterial chemoembolization (TACE) is inefficient at converting unresectable hepatocellular carcinoma (uHCC) to resectable. Treatment with immune checkpoint inhibitors (ICIs) is an emerging strategy for uHCC. Combined therapy of TACE with ICIs is considered to improve the therapeutic effect. CASE PRESENTATION: A 45-year-old man was diagnosed with a bulky HCC under cirrhotic background without distant metastasis. Curative resection was infeasible, and TACE plus tislelizumab (an ICI targeting PD-1) was applied. The treatment course, starting from TACE and followed by tislelizumab one week later, was repeated every four weeks. After three courses, the tumor showed striking shrink in volume with complete radiological response, which permitted salvage resection. Notably, pathological examination found complete necrosis of the tumor with massive infiltration of lymphocytes in the tumor-nontumor interface and extensive granulomatous inflammation in the surrounding nontumor liver, indicating activated immune response synergistically caused by TACE with tislelizumab. The patient is now living well without tumor recurrence for 6 months after surgery.

conclusionTACE in combination with tislelizumab may represent a potent strategy for uHCC. Data from randomized clinical trials are needed to assess its safety and effect in the setting of preoperative downstaging therapy.

Indexed as

downstaging therapyhepatocellular carcinomaimmune checkpoint inhibitorsalvage resectiontislelizumabtransarterial chemoembolization

Identifiers

PMID33869071
PMCPMC8044844
OpenAlexW3149853307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.